{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:57:26Z","timestamp":1793793446545,"version":"4.6.1"},"reference-count":38,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"abstract":"<jats:p>O objetivo deste artigo \u00e9 rever o \u201cestado da arte\u201d dos avan\u00e7os, obst\u00e1culos e estrat\u00e9gias para atingir a erradica\u00e7\u00e3o global da p\u00f3lio. As a\u00e7\u00f5es de controle da poliomielite iniciaram na d\u00e9cada de 1960 com o advento das duas vacinas antipoliomiel\u00edticas, a vacina oral da p\u00f3lio (VOP) e a vacina inativada da p\u00f3lio (VIP). No per\u00edodo de 1985 a 2020, s\u00e3o implementadas estrat\u00e9gias para atingir a meta de erradica\u00e7\u00e3o do poliov\u00edrus selvagem (WPV). Ap\u00f3s o sucesso da interrup\u00e7\u00e3o da transmiss\u00e3o aut\u00f3ctone do WPV na regi\u00e3o da Am\u00e9ricas, foi lan\u00e7ada a meta da erradica\u00e7\u00e3o global. Descrevemos o processo de erradica\u00e7\u00e3o em quatro tempos: (1) O advento das vacinas VIP e VOP iniciou a era do controle da poliomielite; (2) A utiliza\u00e7\u00e3o massiva e simult\u00e2nea da VOP teve impacto significativo sobre a transmiss\u00e3o do poliov\u00edrus selvagem no final da d\u00e9cada de 1970 no Brasil; (3) Pol\u00edticas p\u00fablicas (nacionais e internacionais) decidem pela erradica\u00e7\u00e3o da transmiss\u00e3o aut\u00f3ctone do poliov\u00edrus selvagem nas Am\u00e9ricas e definem as estrat\u00e9gias epidemiol\u00f3gicas para interromper a transmiss\u00e3o; e (4) A implanta\u00e7\u00e3o das estrat\u00e9gias de erradica\u00e7\u00e3o interrompeu a transmiss\u00e3o aut\u00f3ctone do WPV em quase todas as regi\u00f5es do mundo, exceto no Paquist\u00e3o e Afeganist\u00e3o, onde, em 2020, cadeias de transmiss\u00e3o do WPV1 desafiam as estrat\u00e9gias de conten\u00e7\u00e3o do v\u00edrus. Por outro lado, a persist\u00eancia e a dissemina\u00e7\u00e3o da circula\u00e7\u00e3o do poliov\u00edrus derivado da VOP, em pa\u00edses com baixa cobertura vacinal, somadas \u00e0s dificuldades para substituir a VOP pela VIP constituem, atualmente, os obst\u00e1culos para a erradica\u00e7\u00e3o a curto prazo. Finalmente, discutimos as estrat\u00e9gias para superar os obst\u00e1culos e os desafios na era p\u00f3s-erradica\u00e7\u00e3o.<\/jats:p>","DOI":"10.1590\/0102-311x00145720","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T17:52:18Z","timestamp":1604425938000},"source":"Crossref","is-referenced-by-count":13,"title":["A erradica\u00e7\u00e3o da poliomielite em quatro tempos"],"prefix":"10.1590","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4447-020X","authenticated-orcid":false,"given":"Jos\u00e9 Fernando de Souza","family":"Verani","sequence":"first","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1669-9330","authenticated-orcid":false,"given":"Fernando","family":"Laender","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1590\/S0104-59702003000500007","article-title":"A hist\u00f3ria da poliomielite no Brasil e seu controle por imuniza\u00e7\u00e3o","volume":"10","author":"Campos ALV","year":"2003","journal-title":"Hist Ci\u00eanc Sa\u00fade-Manguinhos"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.109.2822.85","article-title":"Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues","volume":"109","author":"Enders JF","year":"1949","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/151.3.420","article-title":"Oral poliovirus vaccine history of its development and use and current challenge to eliminate poliomyelitis from the world","volume":"151","author":"Sabin AB","year":"1985","journal-title":"J Infect Dis"},{"key":"ref4","first-page":"21","article-title":"Advantages and disadvantages of killed and live poliomyelitis vaccines","volume":"56","author":"Melnick JL","year":"1978","journal-title":"Bull World Health Organ"},{"key":"ref5","series-title":"Vaccines.","first-page":"598","volume-title":"Poliovirus vaccine-live","author":"Sutter RW","year":"2013","edition":"6th"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ije\/29.4.757","article-title":"Vaccine-associated paralytic poliomyelitis a retrospective cohort study of acute flaccid paralyses in Brazil","volume":"29","author":"Oliveira LH","year":"2000","journal-title":"Int J Epidemiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1590\/S1413-81232011000200013","article-title":"As campanhas de vacina\u00e7\u00e3o contra a poliomielite no Brasil (1960-1990)","volume":"16","author":"Nascimento DR","year":"2011","journal-title":"Ci\u00eanc Sa\u00fade Colet"},{"key":"ref8","series-title":"Poliomielite no Brasil: do reconhecimento da doen\u00e7a ao fim da transmiss\u00e3o.","author":"Risi Junior JB","year":"2019"},{"key":"ref9","series-title":"Mem\u00f3ria da PolioPlus no Brasil.","year":"1996"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1093\/infdis\/jiw556","article-title":"Rotary's PolioPlus Program lessons learned, transition planning, and legacy","volume":"216","author":"Sever JL","year":"2017","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1093\/infdis\/jiu384","article-title":"Environmental surveillance for polioviruses in the Global Polio Eradication Initiative","volume":"210","author":"Asghar H","year":"2014","journal-title":"J Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"138764","DOI":"10.1016\/j.scitotenv.2020.138764","article-title":"First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community.","volume":"728","author":"Ahmed W","year":"2020","journal-title":"Sci Total Environ"},{"key":"ref13","series-title":"Global eradication of poliomyelitis by the year 2000","year":"1988"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew OM","year":"2002","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew OM","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"ref16","series-title":"Global Polio Surveillance Action Plan, 2018-2020","year":"2019"},{"key":"ref17","first-page":"40","article-title":"Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission","volume":"82","author":"Aylward RB","year":"2004","journal-title":"Bull World Health Organ"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/infdis\/jiu065","article-title":"Poliovirus excretion among persons with primary immune deficiency disorders summary of a seven-country study series","volume":"210","author":"Li L","year":"2014","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fimmu.2017.01103","article-title":"Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder an analysis of the World Health Organization registry","volume":"8","author":"Macklin G","year":"2017","journal-title":"Front Immunol"},{"key":"ref20","series-title":"Polio eradication & endgame strategic plan 2019-2023","year":"2019"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination past, present and future","volume":"10","author":"Bandyopadhyay AS","year":"2015","journal-title":"Future Microbiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.20529\/IJME.2019.060","article-title":"The moral dilemma of the polio eradication","volume":"4","author":"John TJ","year":"2019","journal-title":"Indian J Med Ethics"},{"key":"ref23","first-page":"145","article-title":"Polio vaccines WHO position paper - March, 2016","volume":"91","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"ref24","series-title":"The introduction of IPV, the OPV switch, and risk mitigation."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/jiy739","article-title":"Inactivated poliovirus vaccine supply shortage is there light at the end of the tunnel?","volume":"220","author":"Sutter RW","year":"2019","journal-title":"J Infect Dis"},{"key":"ref26","article-title":"The path towards polio eradication over the 40 years of the Expanded Program on Immunization in the Americas","volume":"41","author":"Pedreira C","year":"2017","journal-title":"Rev Panam Salud P\u00fablica"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine a novel dose sparing immunization schedule","volume":"35","author":"Anand A","year":"2017","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2471\/BLT.18.218370","article-title":"Fractional-dose inactivated poliovirus vaccine, India.","volume":"97","author":"Haldar P","year":"2019","journal-title":"Bull World Health Organ"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme P","year":"2019","journal-title":"Lancet"},{"key":"ref30","series-title":"GPEI strategy for control of cVDPV2, 2020-2021."},{"key":"ref31","series-title":"Statement of the twenty-fifth polio IHR Emergency Committee."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","article-title":"Economic analysis of the Global Polio Eradication Initiative","volume":"29","author":"Tebbens R","year":"2010","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6820a3","article-title":"Progress toward polio eradication - worldwide, January 2017-March 2019","volume":"68","author":"Greene SA","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2019-001633","article-title":"Polio from eradication to systematic, sustained control","volume":"4","author":"Razum O","year":"2019","journal-title":"BMJ Glob Health"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2105\/AJPH.87.6.922","article-title":"Ethical dilemmas in current planning for polio eradication","volume":"87","author":"Taylor CE","year":"1997","journal-title":"Am J Public Health"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2105\/AJPH.87.6.913","article-title":"Ethical dilemmas in worldwide polio eradication programs","volume":"87","author":"Sutter RW","year":"1997","journal-title":"Am J Public Health"},{"key":"ref37","series-title":"The impact of the expanded program on immunization and the polio eradication initiative on health systems in the Americas: final report of the \"Taylor Commission\"","year":"1995"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"S504","DOI":"10.1093\/infdis\/jit232","article-title":"The impact of polio eradication on routine immunization and primary health care a mixed-methods study","volume":"210","author":"Closser S","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csp\/v36s2\/1678-4464-csp-36-s2-e00145720.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T03:43:13Z","timestamp":1611459793000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2020001405005&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":38,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2020]]}},"alternative-id":["S0102-311X2020001405005"],"URL":"https:\/\/doi.org\/10.1590\/0102-311x00145720","relation":{},"ISSN":["1678-4464","0102-311X"],"issn-type":[{"value":"1678-4464","type":"electronic"},{"value":"0102-311X","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"e00145720"}}